Solid dispersions of α-mangostin improve its aqueous solubility through self-assembly of nanomicelles

Journal of Pharmaceutical Sciences

Volumn 101, Issue 2, 2012, Pages 815-825

  Aisha, Abdalrahim F A ^a   Ismail, Zhari ^a   Abu salah, Khalid M ^b   Majid, Amin Malik Shah Abdul ^a,c  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Polymeric drug delivery systems; Polyvinylpyrrolidone; Solid dispersions; Solubility; Solvent evaporation; mangostin

Indexed keywords

1,3,6 TRIHYDROXY 7 METHOXY 2,8 BIS(3 METHYL 2 BUTENYL) 9H XANTHEN 9 ONE; ANION; POVIDONE; PYRENE; UNCLASSIFIED DRUG; XANTHENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CHEMICAL PARAMETERS; CONTROLLED STUDY; CRITICAL MICELLAR CONCENTRATION; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG EFFICACY; DRUG STABILITY; DYNAMIC LIGHT SCATTERING; ENDOCYTOSIS; EVAPORATION; FLUORESCENCE ANALYSIS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIGHT SCATTERING; MICELLE; MOLECULAR PROBE; NANOMICELLE; PARTICLE SIZE; PH; SCANNING ELECTRON MICROSCOPY; SOLID DISPERSION; SOLUBILITY; SOLVENT EVAPORATION; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84455208149     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22806     Document Type: Article

References (32)

1. Ee GC, Daud S, Taufiq-Yap YH, Ismail NH, Rahmani M. 2006. Xanthones from Garcinia mangostana (Guttiferae). Nat Prod Res 20(12):1067-1073.
2. Iikubo K, Ishikawa Y, Ando N, Umezawa K, Nishiyama S. 2002. The first direct synthesis of [alpha]-mangostin, a potent inhibitor of the acidic sphingomyelinase. Tetrahedron Lett 43(2):291-293.
3. Kaomongkolgit R, Chaisomboon N, Pavasant P. 2011. Apoptotic effect of alpha-mangostin on head and neck squamous carcinoma cells. Arch Oral Biol 56(5):483-490.
4. Hung SH, Shen KH, Wu CH, Liu CL, Shih YW. 2009. Alpha-mangostin suppresses PC-3 human prostate carcinoma cell metastasis by inhibiting matrix metalloproteinase-2/9 and urokinase-plasminogen expression through the JNK signaling pathway. J Agric Food Chem 57(4):1291-1298.
5. Doi H, Shibata MA, Shibata E, Morimoto J, Akao Y, Iinuma M, Tanigawa N, Otsuki Y. 2009. Panaxanthone isolated from pericarp of Garcinia mangostana L. suppresses tumor growth and metastasis of a mouse model of mammary cancer. Anticancer Res 29(7):2485-2495.
6. Devi Sampath P, Vijayaraghavan K. 2007. Cardioprotective effect of alpha-mangostin, a xanthone derivative from mangosteen on tissue defense system against isoproterenol-induced myocardial infarction in rats. J Biochem Mol Toxicol 21(6):336-339.
7. Bumrungpert A, Kalpravidh RW, Chitchumroonchokchai C, Chuang CC, West T, Kennedy A, McIntosh M. 2009. Xanthones from mangosteen prevent lipopolysaccharide-mediated inflammation and insulin resistance in primary cultures of human adipocytes. J Nutr 139(6):1185-1191.
8. Pothitirat W, Chomnawang MT, Gritsanapan W. 2010. Anti-acne-inducing bacterial activity of mangosteen fruit rind extracts. Med Princ Pract 19(4):281-286.
9. Suksamrarn S, Suwannapoch N, Phakhodee W, Thanuhiranlert J, Ratananukul P, Chimnoi N, Suksamrarn A. 2003. Antimycobacterial activity of prenylated xanthones from the fruits of Garcinia mangostana. Chem Pharm Bull (Tokyo) 51(7):857-859.
10. Pedraza-Chaverri J, Reyes-Fermin LM, Nolasco-Amaya EG, Orozco-Ibarra M, Medina-Campos ON, Gonzalez-Cuahutencos O, Rivero-Cruz I, Mata R. 2009. ROS scavenging capacity and neuroprotective effect of alpha-mangostin against 3-nitropropionic acid in cerebellar granule neurons. Exp Toxicol Pathol 61(5):491-501.
11. Sakagami Y, Iinuma M, Piyasena KG, Dharmaratne HR. 2005. Antibacterial activity of alpha-mangostin against vancomycin resistant Enterococci (VRE) and synergism with antibiotics. Phytomedicine 12(3):203-208.
12. Kaomongkolgit R, Jamdee K, Chaisomboon N. 2009. Antifungal activity of alpha-mangostin against Candida albicans. J Oral Sci 51(3):401-406.
13. Li L, Brunner I, Han AR, Hamburger M, Kinghorn AD, Frye R, Butterweck V. 2011. Pharmacokinetics of alpha-mangostin in rats after intravenous and oral application. Mol Nutr Food Res 55(Suppl. 1):S67-S74.
14. Kanaujia P, Lau G, Ng WK, Widjaja E, Hanefeld A, Fischbach M, Maio M, Tan RB. 2011. Nanoparticle formation and growth during in vitro dissolution of ketoconazole solid dispersion. J Pharm Sci 100(7):2876-2885.
15. Vasconcelos T, Sarmento B, Costa P. 2007. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 12(23-24):1068-1075.
16. Manju S, Sreenivasan K. 2011. Synthesis and characterization of a cytotoxic cationic polyvinylpyrrolidone-curcumin conjugate. J Pharm Sci 100(2):504-511.
17. Karavas E, Ktistis G, Xenakis A, Georgarakis E. 2006. Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone. Eur J Pharm Biopharm 63(2):103-114.
18. Tang M, Dou H, Sun K. 2006. One-step synthesis of dextran-based stable nanoparticles assisted by self-assembly. Polymer 47(2):728-734.
19. Das S, Suresh PK, Desmukh R. 2010. Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery. Nanomedicine 6(2):318-323.
20. Goddard ED, Turro NJ, Kuo PL, Ananthapadmanabhan KP. 1985. Fluorescence probes for critical micelle concentration determination. Langmuir 1(3):352-355.
21. Jost LM, Kirkwood JM, Whiteside TL. 1992. Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods 147(2):153-165.
22. Abdul-Fattah AM, Bhargava HN. 2002. Preparation and in vitro evaluation of solid dispersions of halofantrine. Int J Pharm 235(1-2):17-33.
23. Craig DQ. 2002. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm 231(2):131-144.
24. Sethia S, Squillante E. 2004. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. Int J Pharm 272(1-2):1-10.
25. Ee GCL, Izzaddin SA, Rahmani M, Sukari MA, Lee HL. 2006. Gamma-mangostin and rubraxanthone, two potential lead compounds for anti-cancer activity against CEM-SS cell line. Nat Prod Sci 12(3):138-143.
26. Ruan LP, Yu BY, Fu GM, Zhu DN. 2005. Improving the solubility of ampelopsin by solid dispersions and inclusion complexes. J Pharm Biomed Anal 38(3):457-464.
27. Konno H, Taylor LS. 2006. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci 95(12):2692-2705.
28. Rajput A, Dominguez San Martin I, Rose R, Beko A, Levea C, Sharratt E, Mazurchuk R, Hoffman RM, Brattain MG, Wang J. 2008. J Surg Res 147(2):276-281.
29. Lee H, Ahn CH, Park TG. 2009. Poly[lactic-co-(glycolic acid)]-grafted hyaluronic acid copolymer micelle nanoparticles for target-specific delivery of doxorubicin. Macromol Biosci 9(4):336-342.
30. Thurn KT, Arora H, Paunesku T, Wu A, Brown EM, Doty C, Kremer J, Woloschak G. 2010. Endocytosis of titanium dioxide nanoparticles in prostate cancer PC-3M cells. Nanomedicine 7(2):123-130.
31. Harush-Frenkel O, Debotton N, Benita S, Altschuler Y. 2007. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem Biophys Res Commun 353(1):26-32.
32. Harush-Frenkel O, Rozentur E, Benita S, Altschuler Y. 2008. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules 9(2):435-443.